Workshop report| Volume 25, ISSUE 7, P603-616, July 2015

Download started.


Report of the second Outcome Measures in Myotonic Dystrophy type 1 (OMMYD-2) international workshop San Sebastian, Spain, October 16, 2013

  • Cynthia Gagnon
    Corresponding author. Faculty of Medicine and Health Sciences, Université de Sherbrooke, Centre de santé et de services sociaux de Jonquière, 2230 de l'Hôpital, C.P. 1200, Jonquière, Québec G7X 7X2, Canada. Tel.: +1 418 695 7777; fax: 1 418 695 7758.
    Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires (GRIMN), Centre de Santé et de Services Sociaux de Jonquière, Jonquière, Québec, Canada

    Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada
    Search for articles by this author
  • Giovanni Meola
    Department of Neurology, IRCCS Policlinico San Donato, University of Milan, Milan, Italy
    Search for articles by this author
  • Luc J. Hébert
    Faculty of Medicine, Université Laval, Laval, Québec, Canada

    Centre for Interdisciplinary Research in Rehabilitation and Social Integration (CIRRIS), Québec, Québec, Canada
    Search for articles by this author
  • Luc Laberge
    ÉCOBES, Cégep de Jonquière, Jonquière, Québec, Canada

    Centre Hospitalier Universitaire de Chicoutimi, Chicoutimi, Québec, Canada
    Search for articles by this author
  • Mario Leone
    Department of Health Sciences, Université du Québec à Chicoutimi, Chicoutimi, Québec, Canada
    Search for articles by this author
  • Chad Heatwole
    Department of Neurology, The University of Rochester Medical Center, Rochester, NY, USA
    Search for articles by this author
Published:January 27, 2015DOI:


      • Expert groups (6) on selection and validation of outcome measures in DM1.
      • Somnolence/Fatigue/Apathy new Special Interest Group.
      • Ongoing research projects to document metrological properties of several instruments.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Neuromuscular Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Tugwell P.
        • Boers M.
        • Brooks P.
        • Simon L.
        • Strand V.
        • Idzerda L.
        OMERACT: an international initiative to improve outcome measurement in rheumatology.
        Trials. 2007; 8: 38
        • Portney L.G.
        • Watkins M.P.
        Foundations of clinical research: applications to practice.
        2nd ed. Prentice Hall Health, Upper Saddle River (NJ)2000
        • Carpentier C.
        • Ghanem D.
        • Fernandez-Gomez F.J.
        • et al.
        Tau exon 2 responsive elements deregulated in myotonic dystrophy type I are proximal to exon 2 and synergistically regulated by MBNL1 and MBNL2.
        Biochim Biophys Acta. 2014; 1842: 654-664
        • Huin V.
        • Vasseur F.
        • Schraen-Maschke S.
        • et al.
        MBNL1 gene variants as modifiers of disease severity in myotonic dystrophy type 1.
        J Neurol. 2013; 260: 998-1003
        • Seedat F.
        • James M.K.
        • Rose M.R.
        Activity rating scales in adult muscle disease: how well do they actually measure?.
        Muscle Nerve. 2014; 50: 24-33
        • Seedat F.
        • James M.K.
        • Rose M.R.
        Activity rating scales in adult muscle disease: what do they actually measure?.
        Muscle Nerve. 2014; 50: 14-23
        • Mokkink L.B.
        • Terwee C.B.
        • Patrick D.L.
        • et al.
        The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study.
        Qual Life Res. 2010; 19: 539-549
        • Heatwole C.
        • Bode R.
        • Johnson N.
        • et al.
        Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure.
        Muscle Nerve. 2014; 49: 906-914
        • Heatwole C.
        • Bode R.
        • Johnson N.
        • et al.
        Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).
        Neurology. 2012; 79: 348-357
        • U.S. Department of Health and Human Services Food and Drug Administration
        Guidance for industry – patient-reported outcome measures: use in medical product development to support labeling claims.
        Center for Drug Evaluation and Research. Center for Biologics Evaluation and Research. Center for Devices and Radiological Health, Silver Spring (MD)2009
        • Johnson N.
        • Luebbe E.
        • Eastwood E.
        • Chin N.
        • Moxley R.
        • Heatwole C.
        Identifying high impact symptoms and issues in congenital and juvenile myotonic dystrophy.
        Neurology. 2012; 78: P05.186
        • Vincent K.A.
        • Carr A.J.
        • Walburn J.
        • Scott D.L.
        • Rose M.R.
        Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL).
        Neurology. 2007; 68: 1051-1057
        • Seesing F.M.
        • van Vught L.E.
        • Rose M.R.
        • Drost G.
        • van Engelen B.G.
        • van der Wilt G.J.
        The Individualized Neuromuscular Quality of Life Questionnaire (INQoL); Cultural translation and psychometric validation for the Dutch population.
        Muscle Nerve. 2014;
        • Peric S.
        • Sansone V.
        • Lavrnica D.
        • et al.
        Serbian validation of the Individualized Neuromuscular Quality of Life Questionnaire (INQoL) in adults with myotonic dystrophy type 1.
        J Neurol Res. 2011; 1: 153-160
        • Sansone V.A.
        • Panzeri M.
        • Montanari M.
        • et al.
        Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases.
        Eur J Neurol. 2010; 17: 1178-1187
        • Sadjadi R.
        • Vincent K.
        • Carr A.
        • et al.
        Validation of the Individualised Neuromuscular Quality of Life for the USA with comparison of the impact of muscle disease on those living in USA versus UK.
        Health Qual Life Outcomes. 2011; 9: 114
        • Cella D.
        • Nowinski C.
        • Peterman A.
        • et al.
        The neurology quality-of-life measurement initiative.
        Arch Phys Med Rehabil. 2011; 92: S28-36
        • Cella D.
        • Riley W.
        • Stone A.
        • et al.
        The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008.
        J Clin Epidemiol. 2010; 63: 1179-1194
        • Gershon R.C.
        • Wagster M.V.
        • Hendrie H.C.
        • Fox N.A.
        • Cook K.F.
        • Nowinski C.J.
        NIH toolbox for assessment of neurological and behavioral function.
        Neurology. 2013; 80: S2-6
        • Birbeck G.L.
        • Kim S.
        • Hays R.D.
        • Vickrey B.G.
        Quality of life measures in epilepsy: how well can they detect change over time?.
        Neurology. 2000; 54: 1822-1827
        • Patrick D.L.
        • Deyo R.A.
        Generic and disease-specific measures in assessing health status and quality of life.
        Med Care. 1989; 27: S217-32
        • Wiklund I.
        • Dimenas E.
        • Wahl M.
        Factors of importance when evaluating quality of life in clinical trials.
        Control Clin Trials. 1990; 11: 169-179
        • Gagnon C.
        • Meola G.
        • Hebert L.J.
        • Puymirat J.
        • Laberge L.
        • Leone M.
        Report of the first Outcome Measures in Myotonic Dystrophy type 1 (OMMYD-1) international workshop: Clearwater, Florida, November 30, 2011.
        Neuromuscul Disord. 2013; 23: 1056-1068
        • Revill S.M.
        • Morgan M.D.
        • Singh S.J.
        • Williams J.
        • Hardman A.E.
        The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease.
        Thorax. 1999; 54: 213-222
        • Jones C.J.
        • Rikli R.E.
        • Beam W.C.
        A 30-s chair-stand test as a measure of lower body strength in community-residing older adults.
        Res Q Exerc Sport. 1999; 70: 113-119
        • Hill K.D.
        A new test of dynamic standing balance for stroke patients: reliability, validity and comparison with healthy elderly.
        Physiother Can. 1996; 48: 257-262
        • Kierkegaard M.
        • Harms-Ringdahl K.
        • Widén Holmqvist L.
        • Tollbäck A.
        Perceived functioning and disability in adults with myotonic dystrophy type 1: a survey according to the International Classification of Functioning, Disability and Health.
        J Rehabil Med. 2009; 41: 512-520
        • Desjardins P.
        Évaluation de la capacité fonctionnelle chez des patients atteints de dystrophie myotonique de type 1. Mémoire de maîtrise.
        (Programme de médecine expérimentale, Université Laval: Quebec)2012
        • Petitclerc E.
        • Hebert L.J.
        • Desrosiers J.
        • Gagnon C.
        Lower limb muscle impairment in myotonic dystrophy type 1: the need for better guidelines.
        Muscle Nerve. 2014;
        • Mathieu J.
        • De Braekeleer M.
        • Prévost C.
        • Boily C.
        Myotonic dystrophy: clinical assessment of muscular disability in an isolated population with presumed homogeneous mutation.
        Neurology. 1992; 42: 203-208
        • Mathieu J.
        • Boivin H.
        • Richards C.L.
        Quantitative motor assessment in myotonic dystrophy.
        Can J Neurol Sci. 2003; 30: 129-136
        • Mathieu J.
        • Boivin H.
        • Meunier D.
        • Gaudreault M.
        • Begin P.
        Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy.
        Neurology. 2001; 56: 336-340
        • Johnson E.R.
        • Abresch R.T.
        • Carter G.T.
        • et al.
        Profiles of neuromuscular diseases. Myotonic dystrophy.
        Am J Phys Med Rehabil. 1995; 74: S104-16
        • Mathieu J.
        • Allard P.
        • Potvin L.
        • Prévost C.
        • Bégin P.
        A 10-year study of mortality in a cohort of patients with myotonic dystrophy.
        Neurology. 1999; 52: 1658-1662
        • Wiles C.M.
        • Busse M.E.
        • Sampson C.M.
        • Rogers M.T.
        • Fenton-May J.
        • van Deursen R.
        Falls and stumbles in myotonic dystrophy.
        J Neurol Neurosurg Psychiatry. 2006; 77: 393-396
        • Sansone V.
        • Gandossini S.
        • Cotelli M.
        • Calabria M.
        • Zanetti O.
        • Meola G.
        Cognitive impairment in adult myotonic dystrophies: a longitudinal study.
        Neurol Sci. 2007; 28: 9-15
        • Hedberg B.
        • Anvret M.
        • Ansved T.
        CTG-repeat length in distal and proximal leg muscles of symptomatic and non-symptomatic patients with myotonic dystrophy: relation to muscle strength and degree of histopathological abnormalities.
        Eur J Neurol. 1999; 6: 341-346
        • Whittaker R.G.
        • Ferenczi E.
        • Hilton-Jones D.
        Myotonic dystrophy: practical issues relating to assessment of strength.
        J Neurol Neurosurg Psychiatry. 2006; 77: 1282-1283
        • Nitz J.C.
        • Burns Y.R.
        • Jackson R.V.
        A longitudinal physical profile assessment of skeletal muscle manifestations in myotonic dystrophy.
        Clin Rehabil. 1999; 13: 64-73
        • Lindeman E.
        • Leffers P.
        • Spaans F.
        • Drukker J.
        • Reulen J.
        Deterioration of motor function in myotonic dystrophy and hereditary motor and sensory neuropathy.
        Scand J Rehabil Med. 1995; 27: 59-64
        • Thompson R.
        • Schoser B.
        • Monckton D.G.
        • Blonsky K.
        • Lochmüller H.
        Patient registries and Trial Readiness in Myotonic Dystrophy – TREAT-NMD/Marigold International Workshop Report.
        Neuromuscul Disord. 2009; 19: 860-866
        • Vandervelde L.
        • Van den Bergh P.Y.K.
        • Goemans N.
        • Thonnard J.-L.
        Activity limitations in patients with neuromuscular disorders: a responsiveness study of the ACTIVLIM questionnaire.
        Neuromuscul Disord. 2009; 19: 99-103
        • Hebert L.J.
        • Remec J.F.
        • Saulnier J.
        • Vial C.
        • Puymirat J.
        The use of muscle strength assessed with handheld dynamometers as a non-invasive biological marker in myotonic dystrophy type 1 patients: a multicenter study.
        BMC Musculoskelet Disord. 2010; 11: 72
        • Mayhew J.E.
        • Florence J.M.
        • Mayhew T.P.
        • et al.
        Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.
        Muscle Nerve. 2007; 35: 36-42
        • Merkel P.A.
        • Seo P.
        • Aries P.
        • et al.
        Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7.
        J Rheumatol. 2005; 32: 2488-2495
        • Park J.D.
        • Radtke R.A.
        Hypersomnolence in myotonic dystrophy: demonstration of sleep onset REM sleep.
        J Neurol Neurosurg Psychiatry. 1995; 58: 512-513
        • Harper P.
        Myotonic dystrophy.
        3rd ed. WB Saunders, London2001 (436 p)
        • Phemister J.
        • Small J.
        Hypersomnia in dystrophia myotonica.
        J Neurol Neurosurg Psychiatry. 1961; 24: 173-175
        • Leygonie-Goldengerg F.
        • Perrier M.
        • Duizabo P.
        • et al.
        Disturbances of wakefulness, sleep and respiratory function in Steinert's disease.
        Rev Neurol (Paris). 1977; 133: 255-277
        • Laberge L.
        • Begin P.
        • Dauvilliers Y.
        • et al.
        A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1.
        J Neurol Neurosurg Psychiatry. 2009; 80: 642-646
        • Kalkman J.S.
        • Schillings M.L.
        • van der Werf S.P.
        • et al.
        Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I.
        J Neurol Neurosurg Psychiatry. 2005; 76: 1406-1409
        • Chaudhuri A.
        • Behan P.O.
        Fatigue in neurological disorders.
        Lancet. 2004; 363: 978-988
        • Rohrer K.
        Myotonia atrophica (dystrophica myotonica).
        Deutsche Ztschr. 1916; 55: 242-248
        • Thomasen E.
        Mental changes in and social conditions of patients with dystrophica myotonica.
        in: Myotonia: Thomsen's disease (myotonica congenita), paramyotonia, and dystrophica myotonica. Aarhuus Stiftsborgtrykkerie A/S, Danmark1948: 154-161
        • Caughey J.E.
        • Myrianthopoulos N.C.
        Dystrophia myotonica and related disorders.
        Charles C. Thomas, Springfield (IL)1963
        • Rubinsztein J.S.
        • Rubinsztein D.C.
        • Goodburn S.
        • Holland A.J.
        Apathy and hypersomnia are common features of myotonic dystrophy.
        J Neurol Neurosurg Psychiatry. 1998; 64: 510-515
        • Di Costanzo A.
        • Mottola A.
        • Toriello A.
        • Di Iorio G.
        • Tedeschi G.
        • Bonavita V.
        Does abnormal neuronal excitability exist in myotonic dystrophy? II. Effects of the antiarrhythmic drug hydroquinidine on apathy and hypersomnia.
        Neurol Sci. 2000; 21: 81-86
        • Gallais B.
        Impact des facteurs génétiques, fonctionnel, psychopathologiques et neuropsychologiques dans l'adaptation à la dystrophie myotonique de Steinert. [Impact of clinical, functional, psychopathological and neuropsychological factors on the adaptation to the Steinert myotonic dystrophy].
        (Université Paris 8 – Vincenne-Saint-Denis. p. 246)2010
        • Hermans M.
        • Merkies I.
        • Laberge L.
        • Blom E.
        • Tennant A.
        • Faber C.
        Fatigue and daytime sleepiness scale in myotonic dystrophy type 1.
        Muscle Nerve. 2013; 47: 89-95
        • Krupp L.B.
        • LaRocca N.G.
        • Muir-Nash J.
        • Steinberg A.D.
        The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.
        Arch Neurol. 1989; 46: 1121-1123
        • Laberge L.
        • Begin P.
        • Montplaisir J.
        • Mathieu J.
        Sleep complaints in patients with myotonic dystrophy.
        J Sleep Res. 2004; 13: 95-100
        • Johns M.W.
        A new method for measuring daytime sleepiness: the Epworth sleepiness scale.
        Sleep. 1991; 14: 540-545
        • Wild D.
        • Grove A.
        • Martin M.
        • et al.
        Principles of good practice for the translation and cultural adaptation process for Patient-Reported Outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.
        Value Health. 2005; 8: 94-104